Summary
- Medpace (MEDP) posted $2.53 billion in full-year 2025 revenue, up 20% over 2024, driven heavily by metabolic trial volume ( Medpace Q4 Press Release).
- Q4 cancellations hit their highest absolute and percentage levels in over a year, dragging the net book-to-bill ratio to 1.04x versus an expected 1.15x ( Q4 Earnings Call Transcript).
- The company repurchased $912.9 million in shares in 2025, with zero debt, funded by a negative working capital model that produced –58.7 days DSO ( Medpace Q4 Highlights).
- CEO August Troendle warned that AI productivity gains in CROs will flow to model providers and clients—not to CRO profit margins ( Earnings Call Transcript).
- 2026 revenue guidance of $2.755B–$2.855B assumes therapeutic mix normalizes away from metabolic concentration, with mid-to-high single-digit headcount growth supporting double-digit revenue growth ( Q4 Press Release).
David L. Berkowitz
Chief Investment Officer and Financial Advisor
Nearly 40 years of experience — from trading and research at a $250 million hedge fund in the early 1990s, to two decades as a portfolio manager, to teaching thousands of executives and employees how to create shareholder value through EVA and value-based management. Now helping individuals and families become shareholders through disciplined investing, concentrated portfolios, and direct stock ownership.
Why Did Metabolic Trials Drive Medpace’s 2025 Revenue and Squeeze Margins at the Same Time?
The metabolic portfolio was the single largest contributor to Medpace’s 2025 revenue. It was also the primary source of turbulence. Biotechnology companies poured money into obesity and diabetes programs, especially GLP-1 receptor agonist trials. Medpace rode that spending wave to $2.53 billion in full-year revenue, a 20% increase over 2024 ( ). Metabolic rose from 22% of revenue in 2024 to 29% in 2025 ( Investing.com Q4 Slides).
Cancellations in the category hit their highest absolute and percentage levels in more than a year ( Q4 Earnings Call). These cancellations weren’t tied to funding failures. Many trials ended early because the drugs produced decisive results ahead of schedule, or sponsors pivoted based on interim data. CEO Troendle said he saw no reason to expect the higher cancellation rate to persist but admitted the Q4 spike was unexpected.
The financial side created separate pressure. Metabolic trials incur unusually high investigator fees, which are reimbursed as out-of-pocket expenses. These pass-through costs inflated the top line without adding proportional profit. Full-year EBITDA margins slipped from 22.8% in 2024 to 22.0% in 2025 ( Medpace Q4 Highlights). Revenue volume was real. The margin profile told a different story.
Did the 1.04x Book-to-Bill Ratio Actually Signal Weak Demand?
A net book-to-bill of 1.04x looked soft on first read. Analysts had expected 1.15x ( GuruFocus Analysis). Shares dropped roughly 14% in premarket trading after the print ( Investing.com Stock Reaction). Management pushed back hard. Gross bookings were described as substantially better than the prior year. The net figure was dragged down by the same metabolic cancellation spike. The ratio, taken alone, misrepresented demand.
The more telling metric was the backlog conversion rate. Medpace ended 2025 with $3.03 billion in backlog and projected that roughly $1.9 billion of that would convert to revenue over the next 12 months—a conversion rate of 23.6% ( Medpace Q4 Press Release). Troendle stated on the call that, with a 23.6% conversion rate, the book-to-bill ratio doesn’t need to be very high to drive growth. The speed at which Medpace converts signed contracts into billed revenue enables the company to sustain double-digit growth without chasing inflated new bookings.
Medpace Q4 2025 — Key Metrics at a Glance
| Metric | Q4 2025 | Full Year 2025 |
|---|---|---|
| Revenue | $708.5M (+32% YoY) | $2.53B (+20% YoY) |
| EBITDA | $160.2M (+20%) | $557.7M (+16.1%) |
| EBITDA Margin | 22.6% | 22.0% |
| Net Book-to-Bill | 1.04x | — |
| Net New Awards | $736.6M (+39.1%) | $2.65B (+18.7%) |
| Ending Backlog | — | $3.03B (+4.3%) |
| Share Repurchases | — | $912.9M |
| Net DSO | –58.7 days | — |
| EPS (Diluted) | $4.67 (+27.2%) | $15.28 (+21.0%) |
Source: Medpace Q4 2025 Press Release, BusinessWire, February 9, 2026.
Why Is Medpace’s AI Strategy Deliberately Cautious?
Every CRO competitor has been making AI claims. Medpace took a different path for 2026: a net-neutral spending assumption. President Jesse Geiger described the plan as focused on internal efficiency and data analytics for site selection. The company expects the cost of building and deploying AI tools to offset any first-year productivity gains. No margin benefit is baked into guidance ( Q4 Earnings Call Transcript).
Troendle went further. He questioned whether AI-driven efficiency gains will ever translate into CRO profit margins. His stated view: those gains will flow to model providers as licensing fees, or get passed to clients through lower pricing. On the earnings call, he said he did not anticipate any net productivity advantage from AI applications in 2026 and that the longer-term gains are likely to be rent paid to model providers ( Earnings Call Highlights).
Geiger added that Medpace is spending on data confidentiality protocols and risk management frameworks before scaling AI use ( Investing.com Transcript). The company treats biotech sponsor data as a liability to protect, not an asset to monetize. That approach stands in sharp contrast to CRO peers racing to market with AI branding.
How Does Negative DSO Fund $913 Million in Buybacks Without Debt?
Medpace reported net Days Sales Outstanding of negative 58.7 days in Q4 2025 ( Medpace Q4 Highlights). That number means Medpace collects cash from clients well before it incurs the associated trial expenses. The result is a negative working capital model that generates free cash flow almost mechanically. Q4 free cash flow hit $188.1 million, a 117.4% conversion rate of EBITDA to free cash flow ( Investing.com Q4 Slides).
That cash flow funded $912.9 million in share repurchases during 2025—2.96 million shares retired. After buying back nearly $1 billion in stock, the company still held $497 million in cash and $821.7 million remaining under its repurchase authorization ( Medpace Q4 Press Release). No external debt was required. The 2026 EPS guidance of $16.68–$17.50 assumes 29.2 million diluted shares and does not include any additional repurchases after December 31, 2025. That means EPS estimates are conservative before additional buybacks.
The balance sheet provides management with the flexibility to continue returning capital at a high rate or deploy cash to other uses without tapping credit markets. Return on equity stood at 91.88% for the year ( Ticker Report)—a figure that reflects both operating efficiency and the aggressive capital return program, which is shrinking the equity base.
How Does Internal Training Keep Headcount Growth Below Revenue Growth?
Medpace hires junior staff and develops them internally. The payoff showed up across 2025 as staff retention held strong through the back half of the year. With fewer people leaving, the company spent less time and money onboarding replacements. Utilization rates rose. Experienced employees handled more work per head.
The math matters for 2026: management expects mid- to high-single-digit headcount growth to support double-digit revenue growth ( Q4 Earnings Call Transcript). CFO Kevin Brady said guidance assumes continued retention and that margin performance will be supported by the resulting productivity improvements. Fewer departures mean the existing workforce absorbs more volume before new hires become necessary. Revenue per employee rises, and the gap between revenue growth and cost growth widens.
Brady added on the call that the lower hiring rate isn’t driven by cost-cutting initiatives or restructuring. It’s a direct byproduct of retention. When experienced people stay, you need fewer new ones ( Investing.com Transcript).
What Does the 2026 Guidance Signal Mean for Long-Term Investors?
Medpace guided 2026 revenue to $2.755 billion–$2.855 billion, representing 8.9%–12.8% growth. EBITDA guidance of $605 million–$635 million implies 8.5%–13.9% growth. Diluted EPS of $16.68–$17.50 represents 9.2%–14.5% growth over 2025 ( Medpace Q4 Press Release). The guidance exceeded consensus estimates of $2.7 billion in revenue and $15.83 EPS ( Ticker Report).
The range assumes a shift away from the metabolic concentration that defined 2025 toward a more balanced therapeutic mix. Reimbursable costs are expected to run at 41%–42% of revenue in 2026, starting higher in the first half and declining as the mix normalizes ( Earnings Call Highlights). If that normalization occurs, pass-through costs should decline as a share of revenue, supporting wider margins on direct-fee work.
The open question for longer-term shareholders is whether Medpace’s specialized small-to-mid biotech client base holds together as large pharma continues to acquire those same companies. Small biopharma clients represented 82% of 2025 revenue, up from 79% in 2024 ( Investing.com Q4 Slides). Troendle addressed the risk directly on the call, noting that acquired clients generally continue their existing work but that Medpace tends to lose those relationships over the long term as they are absorbed into large pharma.
Medpace’s speed of execution, negative working capital model, and low attrition rates all argue for durability. Robert W. Baird upgraded the stock to Outperform with a $564 price target following the report ( Baird Upgrade). How long those advantages persist as the client base consolidates will determine whether the stock’s premium valuation—37x trailing P/E, 1.82x PEG—holds.
────────────────────────────────────────────────────────────
Endnotes
-
Medpace Q4 Press Release – Medpace Holdings, Inc. official fourth quarter and full year 2025 earnings release via BusinessWire.
https://www.businesswire.com/news/home/20260209247649/en/Medpace-Holdings-Inc.-Reports-Fourth-Quarter-and-Full-Year-2025-Results
-
Q4 Earnings Call Transcript – Full transcript of Medpace Q4 2025 earnings call with analyst Q&A, via Investing.com.
https://www.investing.com/news/transcripts/earnings-call-transcript-medpace-q4-2025-beats-expectations-stock-drops-93CH-4497135
-
Q4 Earnings Call Transcript (Globe and Mail / Motley Fool) – Medpace Q4 2025 earnings call transcript with management commentary on AI, cancellations, and staffing.
https://www.theglobeandmail.com/investing/markets/markets-news/motley/133466/medpace-medp-q4-2025-earnings-call-transcript/
-
Medpace Q4 Earnings Call Highlights – Yahoo Finance / Motley Fool summary of key Q4 2025 metrics, cancellation context, and AI commentary.
https://finance.yahoo.com/news/medpace-q4-earnings-call-highlights-205001499.html
-
Investing.com Q4 2025 Slides Analysis – Detailed slide-by-slide breakdown of Medpace Q4 2025 results including revenue composition and customer concentration data.
https://www.investing.com/news/company-news/medpace-q4-2025-slides-revenue-up-32-stock-tumbles-on-guidance-93CH-4497256
-
GuruFocus MEDP Analysis – Analysis of Medpace stock reaction, book-to-bill miss, and valuation metrics following Q4 2025 earnings.
https://www.gurufocus.com/news/8602897/medpace-medp-shares-drop-despite-beating-q4-expectations
-
Ticker Report – FY 2026 Guidance – Medpace FY 2026 earnings guidance, consensus estimates, and analyst ratings summary.
https://www.tickerreport.com/banking-finance/13341164/medpace-nasdaqmedp-releases-fy-2026-earnings-guidance.html
-
Ticker Report – Baird Upgrade – Robert W. Baird upgrade of Medpace to Outperform with $564 price target following Q4 results.
https://www.tickerreport.com/banking-finance/13342011/medpace-nasdaqmedp-raised-to-outperform-at-robert-w-baird.html
-
Morningstar – Medpace Q4 Press Release – Official Medpace Q4 and full-year 2025 results via Morningstar / BusinessWire.
https://www.morningstar.com/news/business-wire/20260209247649/medpace-holdings-inc-reports-fourth-quarter-and-full-year-2025-results
